Skip to main content
Explore URMC
menu

Richard G. Moore, M.D.

Publications

Showing all 84 journal articles & 8 books available

Journal Articles

5/22/2020
James NE, Emerson JB, Borgstadt AD, Beffa L, Oliver MT, Hovanesian V, Urh A, Singh RK, Rowswell-Turner R, DiSilvestro PA, Ou J, Moore RG, Ribeiro JR. "The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes." Scientific reports.. 2020 May 22; 10(1):8558. Epub 2020 May 22.

2/24/2020
Kim KK, Singh RK, Khazan N, Kodza A, Singh NA, Jones A, Sivagnanalingam U, Towner M, Itamochi H, Turner R, Moore RG. "Development of Potent Forchlorfenuron Analogs and Their Cytotoxic Effect in Cancer Cell Lines." Scientific reports.. 2020 Feb 24; 10(1):3241. Epub 2020 Feb 24.

2020
Kim KK, Turner R, Khazan N, Kodza A, Jones A, Singh RK, Moore RG. "Role of trypsin and protease-activated receptor-2 in ovarian cancer." PloS one.. 2020 15(5):e0232253. Epub 2020 May 04.

9/28/2019
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, . "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer." The New England journal of medicine.. 2019 Sep 28; Epub 2019 Sep 28.

7/2019
Moore RG, Blackman A, Miller MC, Robison K, DiSilvestro PA, Eklund EE, Strongin R, Messerlian G. "Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?" Gynecologic oncology.. 2019 Jul 0; 154(1):150-155. Epub 2019 Apr 13.

7/2019
Rowswell-Turner RB, Rutishauser JA, Kim KK, Khazan N, Sivagnanalingam U, Jones AM, Singh RK, Moore RG. "Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer." Translational oncology.. 2019 Jul 0; 12(7):917-924. Epub 2019 May 10.

4/26/2019
James NE, Cantillo E, Yano N, Chichester CO, DiSilvestro PA, Hovanesian V, Rao RSP, Kim KK, Moore RG, Ahsan N, Ribeiro JR. "Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins." Oncotarget.. 2019 Apr 26; 10(31):2959-2972. Epub 2019 Apr 26.

2019
James NE, Oliver MT, Ribeiro JR, Cantillo E, Rowswell-Turner RB, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC. "Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6." Frontiers in pharmacology.. 2019 10:216. Epub 2019 Mar 19.

11/2018
Felix AS, Cohn DE, Brasky TM, Zaino R, Park K, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Randall ME, Brinton LA. "Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study." American journal of obstetrics and gynecology.. 2018 Nov 0; 219(5):459.e1-459.e11. Epub 2018 Aug 07.

9/2018
James NE, Cantillo E, Oliver MT, Rowswell-Turner RB, Ribeiro JR, Kim KK, Chichester CO, DiSilvestro PA, Moore RG, Singh RK, Yano N, Zhao TC. "HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells." Clinical and experimental immunology.. 2018 Sep 0; 193(3):327-340.

2018
Moore, R.G.; Miller, M.C.; Kim, K.; Sivangnanalingham, U.; DuBeshter, B.; Angel, C.; Thomas, S.G.; Seto, K.; Englert, D. ""Ember Trial: "Evaluation of multiple protein and molecular biomarkers to estimate risk of cancer in gynecology patients presenting with a pelvic mass."". 2018; Supplement 1: 178-179.

7/2017
Moore RG, Plante B, Hartnett E, Mitchel J, Raker CA, Vitek W, Eklund E, Lambert-Messerlian G. "Assessment of serum HE4 levels throughout the normal menstrual cycle." American journal of obstetrics and gynecology.. 2017 Jul 0; 217(1):53.e1-53.e9. Epub 2017 Feb 22.

5/2017
Kadan Y, Calvino AS, Katz A, Katz S, Moore RG. "Predictors for lymph nodes involvement in low risk endometrial cancer." Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.. 2017 May 0; 37(4):514-518. Epub 2017 Mar 24.

3/1/2017
Brasky TM, Felix AS, Cohn DE, McMeekin DS, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Park KJ, Ali S, Brinton LA. "Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence." Journal of the National Cancer Institute.. 2017 Mar 1; 109(3):1-10.

2017
Ribeiro JR, Gaudet HM, Khan M, Schorl C, James NE, Oliver MT, DiSilvestro PA, Moore RG, Yano N. "Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer Regulation of the Extracelluar Matrix." Frontiers in oncology.. 2017 7:332. Epub 2018 Jan 22.

1/2016
Lambert-Messerlian G, Plante B, Eklund EE, Raker C, Moore RG. "Levels of antimüllerian hormone in serum during the normal menstrual cycle." Fertility and sterility.. 2016 Jan 0; 105(1):208-13.e1. Epub 2015 Oct 23.

11/21/2015
Wang J, Sibrian-Vazquez M, Escobedo JO, Wang L, Chu YH, Moore RG, Strongin RM. "Templated polymers enable selective capture and release of lysophosphatidic acid in human plasma via optimization of non-covalent binding to functional monomers." The Analyst.. 2015 Nov 21; 140(22):7572-7.

11/16/2015
Kim KK, Han A, Yano N, Ribeiro JR, Lokich E, Singh RK, Moore RG. "Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers." Scientific reports.. 2015 Nov 16; 5:15911. Epub 2015 Nov 16.

11/2015
Lokich E, Palisoul M, Romano N, Craig Miller M, Robison K, Stuckey A, DiSilvestro P, Mathews C, Granai CO, Lambert-Messerlian G, Moore RG. "Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass." Gynecologic oncology.. 2015 Nov 0; 139(2):248-52. Epub 2015 Sep 11.

11/2015
Guthrie ML, Sidhu PS, Hill EK, Horan TC, Nandhikonda P, Teske KA, Yuan NY, Sidorko M, Rodali R, Cook JM, Han L, Silvaggi NR, Bikle DD, Moore RG, Singh RK, Arnold LA. "Antitumor Activity of 3-Indolylmethanamines 31B and PS121912." Anticancer research.. 2015 Nov 0; 35(11):6001-7.

10/15/2015
Kim KK, Abelman S, Yano N, Ribeiro JR, Singh RK, Tipping M, Moore RG. "Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1? in cancer cells." Scientific reports.. 2015 Oct 15; 5:14296. Epub 2015 Oct 15.

10/2015
Felix AS, Scott McMeekin D, Mutch D, Walker JL, Creasman WT, Cohn DE, Ali S, Moore RG, Downs LS, Ioffe OB, Park KJ, Sherman ME, Brinton LA. "Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial." Gynecologic oncology.. 2015 Oct 0; 139(1):70-6. Epub 2015 Sep 01.

9/2015
Felix AS, Brinton LA, McMeekin DS, Creasman WT, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino R, Sherman ME. "Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial." Journal of the National Cancer Institute.. 2015 Sep 0; 107(9)Epub 2015 Jun 18.

5/2015
Wang Y, Han A, Chen E, Singh RK, Chichester CO, Moore RG, Singh AP, Vorsa N. "The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells." International journal of oncology.. 2015 May 0; 46(5):1924-34. Epub 2015 Mar 17.

2/2015
Kadan Y, Fiascone S, McCourt C, Raker C, Granai CO, Steinhoff M, Moore RG. "Predictive factors for the presence of malignant transformation of pelvic endometriosis." European journal of obstetrics, gynecology, and reproductive biology.. 2015 Feb 0; 185:23-7. Epub 2014 Dec 02.

1/31/2015
Wang L, Sibrian-Vazquez M, Escobedo JO, Wang J, Moore RG, Strongin RM. "Spiroguanidine rhodamines as fluorogenic probes for lysophosphatidic acid." Chemical communications : Chem comm. 2015 Jan 31; 51(9):1697-700.

12/2014
Moore RG, Hawkins DM, Miller MC, Landrum LM, Gajewski W, Ball JJ, Allard WJ, Skates SJ. "Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer." Gynecologic oncology.. 2014 Dec 0; 135(3):547-51. Epub 2014 Oct 23.

7/2014
Krivak TC, Lele S, Richard S, Secord AA, Leath CA, Brower SL, Tian C, Moore RG. "A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer." American journal of obstetrics and gynecology.. 2014 Jul 0; 211(1):68.e1-8. Epub 2014 Feb 12.

6/30/2014
Lokich E, Singh RK, Han A, Romano N, Yano N, Kim K, Moore RG. "HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation." Scientific reports.. 2014 Jun 30; 4:5500. Epub 2014 Jun 30.

6/2014
Robison K, Roque D, McCourt C, Stuckey A, DiSilvestro PA, Sung CJ, Steinhoff M, Granai CO, Moore RG. "Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone." Gynecologic oncology.. 2014 Jun 0; 133(3):416-20. Epub 2014 Mar 11.

1/6/2014
Moore RG, Hill EK, Horan T, Yano N, Kim K, MacLaughlan S, Lambert-Messerlian G, Tseng YD, Padbury JF, Miller MC, Lange TS, Singh RK. "HE4 (WFDC2) gene overexpression promotes ovarian tumor growth." Scientific reports.. 2014 Jan 6; 4:3574. Epub 2014 Jan 06.

2014
Cronin B, Robison K, Raker C, Moore RG, Granai C.O., Dizon DS. "Pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer: Is there a role for prolonged therapy?". Clinical Ovarian and Other Gynecologic Cancer. 2014; : 17-20.

11/21/2013
Wang J, Sibrian-Vazquez M, Escobedo JO, Lowry M, Wang L, Chu YH, Moore RG, Strongin RM. "Simple enrichment and analysis of plasma lysophosphatidic acids." The Analyst.. 2013 Nov 21; 138(22):6852-9.

11/2013
Rutherford T, Orr J, Grendys E, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ. "A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer." Gynecologic oncology.. 2013 Nov 0; 131(2):362-7. Epub 2013 Aug 13.

11/2013
Kawar N, Maclaughlan S, Horan TC, Uzun A, Lange TS, Kim KK, Hopson R, Singh AP, Sidhu PS, Glass KA, Shaw S, Padbury JF, Vorsa N, Arnold LA, Moore RG, Brard L, Singh RK. "PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models." Genes & cancer.. 2013 Nov 0; 4(11-12):524-34.

5/2013
Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino R. "Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial." Gynecologic oncology.. 2013 May 0; 129(2):277-84. Epub 2013 Feb 26.

2013
Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore RG, Granai CO, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun C, Horick N, Fritsche H, Bast RC. "A two stage ovarian cancer screening strategy using the risk of ovarian cancer algorithm (ROCA) identifies early stage incident cancers and demonstrates high positive predictive value." Cancer. 2013; 119(19): 3454-3461.

8/2012
Horan TC, Zompa MA, Seto CT, Kim KK, Moore RG, Lange TS. "Description of the cytotoxic effect of a novel drug Abietyl-Isothiocyanate on endometrial cancer cell lines." Investigational new drugs.. 2012 Aug 0; 30(4):1460-70. Epub 2011 Aug 02.

8/2012
Kristjansdottir K, Kim K, Choi JS, Horan TC, Brard L, Moore RG, Singh RK. "7 Methyl indole ethyl isothiocyanate causes ROS mediated apoptosis and cell cycle arrest in endometrial cancer cells." Gynecologic oncology.. 2012 Aug 0; 126(2):252-8. Epub 2012 May 02.

5/2012
Quddus MR, Sung CJ, Zhang C, Moore RG, Ou JJ, Steinhoff MM, Lawrence WD. "The presence and location of epithelial implants and implants with epithelial proliferation may predict a higher risk of recurrence in serous borderline ovarian tumors: a clinicopathologic study of 188 cases." Human pathology.. 2012 May 0; 43(5):747-52. Epub 2011 Nov 01.

5/2012
Bast RC, Skates S, Lokshin A, Moore RG. "Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.. 2012 May 0; 22 Suppl 1:S5-8.

4/13/2012
Kim KK, Lange TS, Singh RK, Brard L, Moore RG. "Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C." BMC cancer.. 2012 Apr 13; 12:147. Epub 2012 Apr 13.

4/2012
Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. "Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders." American journal of obstetrics and gynecology.. 2012 Apr 0; 206(4):351.e1-8. Epub 2011 Dec 30.

4/2012
Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. "Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age." American journal of obstetrics and gynecology.. 2012 Apr 0; 206(4):349.e1-7. Epub 2011 Dec 30.

2/2012
Zhang C, Quddus MR, Sung CJ, Moore RG, Lawrence WD. "Vulvar encapsulated solid papillary carcinoma with neuroendocrine differentiation: a case report." International journal of surgical pathology.. 2012 Feb 0; 20(1):97-100. Epub 2011 Mar 21.

1/2012
Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS, Moore RG. "Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells." International journal of oncology.. 2012 Jan 0; 40(1):227-35. Epub 2011 Sep 12.

1/2012
Lange TS, Horan TC, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, Singh RK. "Cytotoxic properties of Adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cells." Chemical biology & drug design.. 2012 Jan 0; 79(1):92-103. Epub 2011 Nov 04.

1/2012
Singh AP, Lange TS, Kim KK, Brard L, Horan T, Moore RG, Vorsa N, Singh RK. "Purified cranberry proanthocyanidines (PAC-1A) cause pro-apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells." International journal of oncology.. 2012 Jan 0; 40(1):99-108. Epub 2011 Oct 06.

2012
Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar N, Yano N, Chu SR, Mao Q, Brard L, DePaepe ME, Padbury JF, Arnold LA, Brodsky A, Shen TL, Singh RK. "Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model." PloS one.. 2012 7(4):e34443. Epub 2012 Apr 03.

11/2011
Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, Singh RK. "Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines." Gynecologic oncology.. 2011 Nov 0; 123(2):370-8. Epub 2011 Jul 30.

10/2011
Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. "Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.. 2011 Oct 0; 21(7):1185-90.

8/2011
Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, Skates SJ. "Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass." Obstetrics and gynecology.. 2011 Aug 0; 118(2 Pt 1):280-8.

7/2011
Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG. "Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines." Gynecologic oncology.. 2011 Jul 0; 122(1):183-9. Epub 2011 May 06.

4/29/2011
Kim KK, Singh RK, Strongin RM, Moore RG, Brard L, Lange TS. "Organometallic iron(III)-salophene exerts cytotoxic properties in neuroblastoma cells via MAPK activation and ROS generation." PloS one.. 2011 Apr 29; 6(4):e19049. Epub 2011 Apr 29.

3/2011
Orr JW, Moore RG. "Breast cancer: pursuing state-of-the-art care. Foreword." Clinical obstetrics and gynecology.. 2011 Mar 0; 54(1):83-4.

3/2011
Pandya S, Moore RG. "Breast development and anatomy." Clinical obstetrics and gynecology.. 2011 Mar 0; 54(1):91-5.

2/2011
Robison K, Holman LL, Moore RG. "Update on sentinel lymph node evaluation in gynecologic malignancies." Current opinion in obstetrics & gynecology.. 2011 Feb 0; 23(1):8-12.

9/2010
Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. "Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass." American journal of obstetrics and gynecology.. 2010 Sep 0; 203(3):228.e1-6. Epub 2010 May 14.

9/2010
Moore RG, Maclaughlan S. "Current clinical use of biomarkers for epithelial ovarian cancer." Current opinion in oncology.. 2010 Sep 0; 22(5):492-7.

2/2010
Moore RG, MacLaughlan S, Bast RC. "Current state of biomarker development for clinical application in epithelial ovarian cancer." Gynecologic oncology.. 2010 Feb 0; 116(2):240-5. Epub 2009 Oct 31.

2010
Krotz SP, Robins JC, Ferruccio TM, Moore RG, Steinhoff MM, Morgan JR, Carson S. "In vitro maturation of oocytes via the pre-fabricated self-assembled artificial human ovary." Journal of Assisted Reproductive Genetics. 2010; 27(12): 743-750.

12/2009
Clements A, Robison K, Granai C, Steinhoff MM, Scalia-Wilbur J, Moore RG. "A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.. 2009 Dec 0; 19(9):1591-4.

1/2009
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. "A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass." Gynecologic oncology.. 2009 Jan 0; 112(1):40-6. Epub 2008 Oct 12.

2009
Rardin CR, Moore RG, Ward RM, Myers DL. "Recurrent thigh abscess with necrotizing fasciitis from a retained transobturator sling segment." Journal of Minimally Invasive Gynecology. 2009; 16(1): 84-87.

2009
Allard JW and Moore RG. "The novel biomarker HE4 improves the sensitivity of CA125 alone for monitoring and differential diagnosis of ovarian cancer." Clinical Laboratories International. 2009; 3: 20-21.

8/2008
Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC, Lu K. "Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus." Gynecologic oncology.. 2008 Aug 0; 110(2):196-201. Epub 2008 May 21.

4/2008
Moore RG, Robison K, Brown AK, DiSilvestro P, Steinhoff M, Noto R, Brard L, Granai CO. "Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial." Gynecologic oncology.. 2008 Apr 0; 109(1):65-70. Epub 2008 Feb 05.

2/2008
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. "The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass." Gynecologic oncology.. 2008 Feb 0; 108(2):402-8. Epub 2007 Dec 03.

2008
Moore RG, Robison K, Steinhoff M. "The utility of immunohistochemical staining for detection of metastatic disease in sentinel lymph nodes. Invited editorial". Gynecologic Oncology. 2008; 111(1): 159.

9/20/2007
Moore RG, Bast RC. "How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2007 Sep 20; 25(27):4159-61. Epub 2007 Aug 13.

9/2007
Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC. "Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment." Gynecologic oncology.. 2007 Sep 0; 106(3):490-7. Epub 2007 May 25.

2/2007
Gordinier ME, Dizon DS, Weitzen S, Disilvestro PA, Moore RG, Granai CO. "Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer." Journal of palliative medicine.. 2007 Feb 0; 10(1):61-6.

2007
Madom LM, Brown AK, Lui F, Moore RG, Granai CO, DiSilvestro PA. "Lower uterine segment involvement as a predictor for lymph node spread in endometrial carcinoma." Gynecologic Oncology. 2007; 107(1): 75-78.

10/2006
Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gordinier ME, Moore RG, Granai CO. "The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients." Gynecologic oncology.. 2006 Oct 0; 103(1):176-80. Epub 2006 Mar 27.

4/2006
Robison K, Steinhoff MM, Granai CO, Brard L, Gajewski W, Moore RG. "Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes." Gynecologic oncology.. 2006 Apr 0; 101(1):24-7. Epub 2005 Oct 24.

2006
Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, DiSilvestro P, Gordinier M, Moore RG, Tejada-Berges T, Pires L, Legare R, Granai C.O.. "Two more for Good Measure: Six versus Eight Cycles of Carboplatin and Paclitaxel as Adjuvant Treatment for Epithelial Ovarian Cancer." Gynecologic Oncology. 2006; 100: 417-421.

2006
Dizon DS, Schwartz J, Rojan A, Miller J, Pires L, DiSilvestro P, Gordinier ME, Moore RG, Granai C.O. and Legare RG. "Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program." Gynecologic Oncology. 2006; 100: 149-151.

3/2005
Brown AK, Moore RG. "HPV vaccines--why aren't they the answer yet?" Medicine and health, Rhode Island.. 2005 Mar 0; 88(3):74-9.

4/2004
Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. "Incidence of metastasis to the ovaries from nongenital tract primary tumors." Gynecologic oncology.. 2004 Apr 0; 93(1):87-91.

11/2003
Moore RG, Granai CO, Gajewski W, Gordinier M, Steinhoff MM. "Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining." Gynecologic oncology.. 2003 Nov 0; 91(2):378-82.

6/2003
Moore RG, DePasquale SE, Steinhoff MM, Gajewski W, Steller M, Noto R, Falkenberry S. "Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva." Gynecologic oncology.. 2003 Jun 0; 89(3):475-9.

4/2002
Moore RG, Steinhoff MM, Granai CO, DeMars LR. "Vulvar epithelioid sarcoma in pregnancy." Gynecologic oncology.. 2002 Apr 0; 85(1):218-22.

4/2002
Teasdale JD, Moore RG, Hayhurst H, Pope M, Williams S, Segal ZV. "Metacognitive awareness and prevention of relapse in depression: empirical evidence." Journal of consulting and clinical psychology.. 2002 Apr 0; 70(2):275-87.

Urh A, Romano N, Kim KK, Ribeiro J, Raker C, Yano N, Hovanessian G, Schorl C, Singh R, Moore RG. "HE4 expression predicts CD8+ tumor infiltrating lymphocytes (TILs) and PD-L1 status in Epithelial Ovarian Cancer". Scientific Reports, Nature. .

Books & Chapters

2011
Chapter Title: Breast Development and Anatomy
Book Title: Clinical Obstetrics and Gynecology
Author List: Sonali Pandya and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins2011

2011
Chapter Title: Management of Ovarian Cysts and Adnexal Masses
Book Title: Precis Gynecology
Author List: Richard G. Moore and Shannon MacLaughlan
Published By: Precis: Gynecology2011

2011
Chapter Title: Forward
Book Title: Clinical Obstetrics and Gynecology,
Author List: James W. Orr and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins2011

2009
Chapter Title: Biomarkers and ovarian cancer
Book Title: Ovarian Cancer: State of the Art
Author List: Richard G. Moore and Robert Bast, Jr.
Published By: Remedica Medical Education and Publishing2009

2006
Chapter Title: Abnormal Cervical Cytology
Book Title: OBGYN in Review
Author List: Paul DiSilvestro & Richard G. Moore.
Published By: OBGYN in Review2006

2006
Chapter Title: Post-Operative Care and Complications
Book Title: OBGYN in Review
Author List: Richard G. Moore & Paul DiSilvestro.
Published By: OBGYN2006

2006
Chapter Title: Diseases and abnormalities of the vulva, vagina and adjacent epithelial sites
Book Title: Biomedical Communications
Author List: Wright CV, Bryson P, Collado CM, Guijon F, Indman P, McKinney CD, Mercado LC, Moore RG, Powell JL, Rojas TS, Shier RM.
Published By: Biomedical Communications2006

2003
Chapter Title: Endometrial cancer, PIER Module
Book Title: Pier.acponline.org
Author List: Moore RG, Steller MA
Published By: American college of physicians2003